Regeneron Pharmaceuticals is constructing an $800 million manufacturing campus in East Greenbush, N.Y. The complex is now in the third and final phase of development, which includes an $188 million, 346,000-sf production facility; a 240,000-sf lab and office building; and a six-story, 1,050-space parking garage. BBL Construction Services is managing the project with completion expected by 2022.
The University of Lincoln broke ground in March of 2020 on the Centre of Excellence in Agri-Food Technology in the United Kingdom. Supporting the development of new technologies and resources for the region's agribusiness sector, the building will provide microbiology and chemistry labs, a sophisticated test kitchen and sensory suite, seminar rooms, and collaboration spaces. Willmott Dixon was awarded the £7 million construction contract for the innovation center, which will accommodate a community of leading industrial scientists and their support teams.
Fujifilm Diosynth Biotechnologies began construction in March of 2020 on a $14.5 million campus in Billingham in the United Kingdom. Designed by Ryder Architecture, the project will support the creation of innovative biologic, vaccine, and gene therapy products. Accommodating approximately 300 employees, the campus will feature a 42,000-sf office building with an inviting welcome center. Completion is expected in March of 2021. Additional R&D laboratories and manufacturing facilities will be delivered in a subsequent phase of development.
Amicus Therapeutics opened the $25 million Global Research and Gene Therapy Center of Excellence in March of 2020 in Philadelphia. Accommodating up to 200 employees, the 75,000-sf project provides collaborative labs and offices to support the discovery and development of new therapies for rare metabolic diseases.
East Carolina University is constructing the $90 million Life Sciences and Biotechnology Building in Greenville, N.C. Designed by Lord Aeck Sargent, the 141,500-sf facility will provide wet bench and computational labs for programs in biotechnology, biophysics, biofuels, environmental engineering, imaging, and sensor development. Enabling students to engage in collaborative research with academic and industry partners, the four-story structure will include classrooms, lecture halls, administrative offices, core labs, and support spaces.
Audentes Therapeutics is planning to construct a $109 million gene therapy manufacturing facility in Sanford, N.C. The 135,000-sf project will support the production of genetic medicines based on adeno-associated virus vectors for the treatment of rare neuromuscular diseases. The center is expected to be operational by 2021. Audentes Therapeutics is a subsidiary of Astellas Pharma.
Athenex is constructing a $210 million pharmaceutical plant in Dunkirk, N.Y. Supporting the production of advanced cancer therapies, the 409,000-sf complex will provide research, office, manufacturing, and warehouse space. General contractor Exyte broke ground on the facility in May of 2018, and commercial operations will commence at the site in early 2022. The project is part of a strategic infrastructure development plan to enable Athenex to offer vertically integrated oncology services from discovery through marketing.
Merck KGaA broke ground in early 2020 on the $275 Biotech Development Center in Corsier-sur-Vevey, Switzerland. Constructed adjacent to the company's existing commercial manufacturing campus, the 169,000-sf project will provide advanced research, development, and production facilities to support the creation of innovative biological compounds for clinical studies.
Foghorn Therapeutics broke ground in January of 2020 on its 60,000-sf headquarters in Cambridge, Mass. Located in Kendall Square, the facility will provide chemistry and biology labs, open offices, conference rooms, huddle rooms, and an employee café. Foghorn will occupy over three floors in the building, which is owned by Alexandria Real Estate Equities and managed by CBRE.
St. Jude's Children's Research Hospital is constructing the $13.4 million Shared Resource Center in Memphis, Tenn. Accommodating 60 employees, the project will provide core laboratories and instrumentation suites to accelerate the discovery of new treatments for pediatric cancer and other diseases. Created inside an existing 300,000-sf warehouse, the 100,000-sf center will house:
The University of California, Davis has selected Wexford Science + Technology and GMH Capital Partners to develop the first phase of Aggie Square in Sacramento. The two firms will finance, design, construct, and own the facilities, which will include 250,000 sf of classroom and co-working space, 500,000 sf of engineering, science, and technology space, 30,000 sf of ground-floor public space, and approximately 200 housing units.
HALIX opened a 72,000-sf biopharmaceutical development and manufacturing center in November of 2019 at Leiden Bio Science Park in the Netherlands. The five-story structure provides BSL-2 cleanrooms with unidirectional process flows that can easily be upgraded to BSL-3 as needed. A manufacturing line with a 250-liter bioreactor capacity supports the production of viral vaccines and viral vectors, while a separate protein manufacturing area accommodates single-use bioreactors with a capacity of up to 1,000 liters.
Thermo Fisher Scientific opened a $90 million viral vector facility in December of 2019 in Lexington, Mass. Featuring specialized GMP laboratories, the 50,000-sf project will accommodate the development, testing, and manufacture of viral vectors for the creation of gene and cell therapies. The center will act as a CDMO (contract development and manufacturing organization) site and will offer services including from drug development through clinical trials and commercial production.
Florida Atlantic University hosted a ceremonial groundbreaking for its $35 million Neuroscience Building in Jupiter in November of 2019. Construction will begin in summer of 2020 on the facility, which will provide shared research labs, faculty offices, a business incubator, and instructional space for programs in neuroscience, biotechnology, bioengineering, bioinformatics, and chemistry. The 58,000-sf project is strategically sited on the John D.
AZI is constructing an 85,000-sf isoptope production and research facility in Bunker Hill, Ind. The $44.5 million project includes the expansion of a 55,000-sf shell building by 30,000 sf to accommodate a 280,000-pound 70MeV cyclotron. The existing structure was purchased at a cost of $2.8 million. AZI (Arizona Isotopes Science Research Corp.) is based in Phoenix and supplies medical isotopes to companies and institutions worldwide. The facility is strategically sited near the Grissom Aeroplex, a public and military airport with a 12,500-sf runway.
